 SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 GLOBE NEWSWIRE -- Pliant Therapeutics, Inc. Nasdaq: PLRX, a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue a pre-market press release and conduct a conference call and webcast on Tuesday, September 7, 2021, to discuss interim clinical data from an ongoing Phase 2a positron emission tomography PET imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis IPF. 